Daraxonrasib in First-Line mPDAC: Cancer Research | April 2026

Introduction

Metastatic pancreatic ductal adenocarcinoma remains one of the most lethal cancers, with a 5-year survival of approximately 3%. Current first-line chemotherapy offers limited benefit and significant toxicity. Given that over 90% of PDAC cases harbor RAS mutations, targeting this pathway has long been a major therapeutic goal. Daraxonrasib is a novel oral agent designed to inhibit active RAS across multiple mutations, offering a potentially transformative approach.

Problem Statement

Effective and tolerable first-line targeted therapies for RAS-mutant pancreatic cancer are lacking, despite the central role of RAS in disease biology.

Summary

This early-phase study evaluates daraxonrasib as first-line monotherapy in RAS-mutant mPDAC and demonstrates encouraging preliminary results. The treatment showed a manageable safety profile, with common adverse effects including rash, diarrhea, and mucositis, but importantly no grade 4 or 5 toxicities. Although dose modifications were frequent, treatment discontinuation was rare.

Efficacy signals are particularly noteworthy. Objective response rates approached 50%, with disease control rates exceeding 90%, which compares favorably to standard chemotherapy benchmarks. Additionally, progression-free survival at 6 months was 71%, and overall survival at 6 months reached 83%, suggesting meaningful clinical activity.

A key strength of the study is the incorporation of circulating tumor DNA (ctDNA) analysis, where all evaluable patients demonstrated significant reduction in RAS mutation burden, and more than half achieved complete clearance—supporting a strong biological effect.

Overall, daraxonrasib represents a promising targeted strategy in a historically treatment-resistant disease. These findings justify ongoing phase 3 trials and signal a potential shift toward molecularly driven first-line therapy in pancreatic cancer.